In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Evolent Health Inc (NYSE: EVH) was $31.74 for the day, up 0.38% from the previous closing price of $31.62. In other words, the price has increased by $0.38 from its previous closing price. On the day, 1.57 million shares were traded. EVH stock price reached its highest trading level at $32.02 during the session, while it also had its lowest trading level at $31.2.
Ratios:
Our analysis of EVH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.46. For the most recent quarter (mrq), Quick Ratio is recorded 1.08 and its Current Ratio is at 1.08. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.77.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on August 09, 2024, Upgraded its rating to Buy and sets its target price to $33 from $28 previously.
On April 22, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $40.
On March 01, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $45.Oppenheimer initiated its Outperform rating on March 01, 2024, with a $45 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 22 ’24 when McCarthy Daniel Joseph sold 23,693 shares for $30.89 per share. The transaction valued at 731,790 led to the insider holds 198,809 shares of the business.
McCarthy Daniel Joseph sold 10,469 shares of EVH for $339,008 on Aug 23 ’24. The PRESIDENT now owns 188,340 shares after completing the transaction at $32.38 per share. On Aug 22 ’24, another insider, Weinberg Jonathan, who serves as the General Counsel of the company, sold 42,140 shares for $31.20 each. As a result, the insider received 1,314,706 and left with 167,027 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 3691044608 and an Enterprise Value of 4360915968. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.57 while its Price-to-Book (P/B) ratio in mrq is 3.46. Its current Enterprise Value per Revenue stands at 1.853 whereas that against EBITDA is 32.005.
Stock Price History:
Over the past 52 weeks, EVH has reached a high of $35.00, while it has fallen to a 52-week low of $17.98. The 50-Day Moving Average of the stock is 39.74%, while the 200-Day Moving Average is calculated to be 14.49%.
Shares Statistics:
EVH traded an average of 2.56M shares per day over the past three months and 3952440 shares per day over the past ten days. A total of 113.89M shares are outstanding, with a floating share count of 110.66M. Insiders hold about 4.84% of the company’s shares, while institutions hold 118.48% stake in the company. Shares short for EVH as of 1722384000 were 14334569 with a Short Ratio of 6.20, compared to 1719532800 on 12528491. Therefore, it implies a Short% of Shares Outstanding of 14334569 and a Short% of Float of 14.249999999999998.
Earnings Estimates
At present, 11.0 analysts are actively evaluating the performance of Evolent Health Inc (EVH) in the stock market.The consensus estimate for the next quarter is $0.38, with high estimates of $0.47 and low estimates of $0.27.
Analysts are recommending an EPS of between $1.5 and $0.99 for the fiscal current year, implying an average EPS of $1.35. EPS for the following year is $1.72, with 11.0 analysts recommending between $2.23 and $0.97.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $642.8M to a low estimate of $619M. As of the current estimate, Evolent Health Inc’s year-ago sales were $509.24MFor the next quarter, 14 analysts are estimating revenue of $662.42M. There is a high estimate of $678.16M for the next quarter, whereas the lowest estimate is $645M.
A total of 15 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $2.6B, while the lowest revenue estimate was $2.56B, resulting in an average revenue estimate of $2.58B. In the same quarter a year ago, actual revenue was $1.96BBased on 15 analysts’ estimates, the company’s revenue will be $2.93B in the next fiscal year. The high estimate is $3.07B and the low estimate is $2.57B.
